VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing, marking a potential shift in how preclinical efficacy studies are conducted in oncology.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. The company said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications of this announcement extend beyond animal welfare. By aligning with FDA’s evolving regulatory framework, which encourages NAMs to replace, reduce, or refine animal testing, VERAXA positions itself at the forefront of a broader industry trend. If widely adopted, such methods could shorten preclinical development timelines, lower costs, and potentially bring therapies to patients faster. The company’s ability to generate clinically relevant data from a small number of animals also addresses growing ethical and practical concerns about extensive animal use in cancer research.
VERAXA’s NAM strategy is part of its broader effort to build a premier engine for the discovery and development of next-generation antibody-based therapeutics. Powered by transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. Founded on scientific breakthroughs at the European Molecular Biology Laboratory, VERAXA aims to translate cutting-edge research into innovative cancer treatments.
For investors and industry observers, the update signals potential operational efficiencies and regulatory alignment that could enhance VERAXA’s competitive position. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA. To view the full press release, visit https://ibn.fm/9YRJw.
BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
